The Association of Employers of Innovative Pharmaceutical Companies INFARMA has just published its annual "Access Gap" report, summarizing Polish patients' access to innovative therapies. How would you comment on the latest results?
According to data published by INFARMA in its third Access GAP report, access to modern therapies and diagnostic solutions is increasing in all Visegrad countries. Poland is also seeing a significant improvement, up 16 points from 2022. This is good news for Polish patients. Progress is seen mainly in two areas: oncology and rare diseases. In chronic diseases, on the other hand, we have only a slight improvement, so there is still more to work on. The most pressing challenge remains the prolonged time between registration and reimbursement of drugs, which has increased from 940 to 1,029 days, proving the need for further concerted efforts in this area.
Staying on the topic of innovat... To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].Content locked
